MDM2 and dedifferentiated liposarcoma: A recent multidisciplinary position statement goes further and recommends; given the increasing role of histology-specific therapeutic approaches, individuals with a suspected DDLPS should have pathology reviewed at a center with sarcoma expertise, and the use of molecular diagnostics, including the assessment of MDM2 amplification by FISH, or, in the appropriate clinical context, overexpression by IHC, can help confirm a diagnosis of DDLPS [13].